Global Drug Delivery in Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 Drug Delivery in Cancer Market Overview

• 1.1 Product Overview and Scope of Drug Delivery in Cancer
• 1.2 Classification of Drug Delivery in Cancer by Types
  • 1.2.1 Global Drug Delivery in Cancer Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global Drug Delivery in Cancer Revenue Market Share by Types in 2018
  • 1.2.3 Liposomes
  • 1.2.4 PEGylated Proteins & Polypeptides
  • 1.2.5 Polymer Nanoparticle
  • 1.2.6 Protein–drug Conjugates
  • 1.2.7 Others
• 1.3 Global Drug Delivery in Cancer Market by Application
  • 1.3.1 Global Drug Delivery in Cancer Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospitals & Clinic
  • 1.3.3 Cancer Treatment Centers
  • 1.3.4 Others
• 1.4 Global Drug Delivery in Cancer Market by Regions
  • 1.4.1 Global Drug Delivery in Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) Drug Delivery in Cancer Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Drug Delivery in Cancer Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drug Delivery in Cancer Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Drug Delivery in Cancer Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drug Delivery in Cancer Status and Prospect (2014-2024)
• 1.5 Global Market Size of Drug Delivery in Cancer (2014-2024)

2 Manufacturers Profiles

• 2.1 Amgen
  • 2.1.1 Business Overview
  • 2.1.2 Drug Delivery in Cancer Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Amgen Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Teva
  • 2.2.1 Business Overview
  • 2.2.2 Drug Delivery in Cancer Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Teva Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 UCB (Union Chimique Belge)
  • 2.3.1 Business Overview
  • 2.3.2 Drug Delivery in Cancer Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 UCB (Union Chimique Belge) Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Roche
  • 2.4.1 Business Overview
  • 2.4.2 Drug Delivery in Cancer Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Roche Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Celgene
  • 2.5.1 Business Overview
  • 2.5.2 Drug Delivery in Cancer Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Celgene Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 Sanofi
  • 2.6.1 Business Overview
  • 2.6.2 Drug Delivery in Cancer Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 Sanofi Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Merck
  • 2.7.1 Business Overview
  • 2.7.2 Drug Delivery in Cancer Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Merck Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Johnson & Johnson
  • 2.8.1 Business Overview
  • 2.8.2 Drug Delivery in Cancer Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Johnson & Johnson Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Takeda
  • 2.9.1 Business Overview
  • 2.9.2 Drug Delivery in Cancer Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Takeda Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Gilead Sciences
  • 2.10.1 Business Overview
  • 2.10.2 Drug Delivery in Cancer Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Gilead Sciences Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.11 Pfizer
  • 2.11.1 Business Overview
  • 2.11.2 Drug Delivery in Cancer Type and Applications
    • 2.11.2.1 Product A
    • 2.11.2.2 Product B
  • 2.11.3 Pfizer Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.12 Dr Reddy
  • 2.12.1 Business Overview
  • 2.12.2 Drug Delivery in Cancer Type and Applications
    • 2.12.2.1 Product A
    • 2.12.2.2 Product B
  • 2.12.3 Dr Reddy Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.13 Samyang Biopharmaceuticals
  • 2.13.1 Business Overview
  • 2.13.2 Drug Delivery in Cancer Type and Applications
    • 2.13.2.1 Product A
    • 2.13.2.2 Product B
  • 2.13.3 Samyang Biopharmaceuticals Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.14 Tolmar
  • 2.14.1 Business Overview
  • 2.14.2 Drug Delivery in Cancer Type and Applications
    • 2.14.2.1 Product A
    • 2.14.2.2 Product B
  • 2.14.3 Tolmar Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.15 Astellas
  • 2.15.1 Business Overview
  • 2.15.2 Drug Delivery in Cancer Type and Applications
    • 2.15.2.1 Product A
    • 2.15.2.2 Product B
  • 2.15.3 Astellas Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.16 AMAG Pharmaceuticals
  • 2.16.1 Business Overview
  • 2.16.2 Drug Delivery in Cancer Type and Applications
    • 2.16.2.1 Product A
    • 2.16.2.2 Product B
  • 2.16.3 AMAG Pharmaceuticals Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.17 AstraZeneca
  • 2.17.1 Business Overview
  • 2.17.2 Drug Delivery in Cancer Type and Applications
    • 2.17.2.1 Product A
    • 2.17.2.2 Product B
  • 2.17.3 AstraZeneca Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.18 AbbVie
  • 2.18.1 Business Overview
  • 2.18.2 Drug Delivery in Cancer Type and Applications
    • 2.18.2.1 Product A
    • 2.18.2.2 Product B
  • 2.18.3 AbbVie Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.19 Novartis
  • 2.19.1 Business Overview
  • 2.19.2 Drug Delivery in Cancer Type and Applications
    • 2.19.2.1 Product A
    • 2.19.2.2 Product B
  • 2.19.3 Novartis Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.20 Aspen
  • 2.20.1 Business Overview
  • 2.20.2 Drug Delivery in Cancer Type and Applications
    • 2.20.2.1 Product A
    • 2.20.2.2 Product B
  • 2.20.3 Aspen Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.21 Shire (Baxalta)
  • 2.21.1 Business Overview
  • 2.2.2 Drug Delivery in Cancer Type and Applications
    • 2.21.2.1 Product A
    • 2.21.2.2 Product B
  • 2.21.3 Shire (Baxalta) Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.22 Breckenridge Pharmaceuticals
  • 2.22.1 Business Overview
  • 2.22.2 Drug Delivery in Cancer Type and Applications
    • 2.22.2.1 Product A
    • 2.22.2.2 Product B
  • 2.22.3 Breckenridge Pharmaceuticals Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.23 Galen Pharmaceuticals
  • 2.23.1 Business Overview
  • 2.23.2 Drug Delivery in Cancer Type and Applications
    • 2.23.2.1 Product A
    • 2.23.2.2 Product B
  • 2.23.3 Galen Pharmaceuticals Drug Delivery in Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global Drug Delivery in Cancer Market Competition, by Players

• 3.1 Global Drug Delivery in Cancer Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 Drug Delivery in Cancer Players Market Share
  • 3.2.2 Top 10 Drug Delivery in Cancer Players Market Share
• 3.3 Market Competition Trend

4 Global Drug Delivery in Cancer Market Size by Regions

• 4.1 Global Drug Delivery in Cancer Revenue and Market Share by Regions
• 4.2 North America Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 4.3 Europe Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 4.5 South America Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

5 North America Drug Delivery in Cancer Revenue by Countries

• 5.1 North America Drug Delivery in Cancer Revenue by Countries (2014-2019)
• 5.2 USA Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 5.3 Canada Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 5.4 Mexico Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

6 Europe Drug Delivery in Cancer Revenue by Countries

• 6.1 Europe Drug Delivery in Cancer Revenue by Countries (2014-2019)
• 6.2 Germany Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 6.3 UK Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 6.4 France Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 6.5 Russia Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 6.6 Italy Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Drug Delivery in Cancer Revenue by Countries

• 7.1 Asia-Pacific Drug Delivery in Cancer Revenue by Countries (2014-2019)
• 7.2 China Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 7.3 Japan Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 7.4 Korea Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 7.5 India Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

8 South America Drug Delivery in Cancer Revenue by Countries

• 8.1 South America Drug Delivery in Cancer Revenue by Countries (2014-2019)
• 8.2 Brazil Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 8.3 Argentina Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 8.4 Colombia Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Drug Delivery in Cancer by Countries

• 9.1 Middle East and Africa Drug Delivery in Cancer Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 9.3 UAE Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 9.4 Egypt Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)
• 9.6 South Africa Drug Delivery in Cancer Revenue and Growth Rate (2014-2019)

10 Global Drug Delivery in Cancer Market Segment by Type

• 10.1 Global Drug Delivery in Cancer Revenue and Market Share by Type (2014-2019)
• 10.2 Global Drug Delivery in Cancer Market Forecast by Type (2019-2024)
• 10.3 Liposomes Revenue Growth Rate (2014-2024)
• 10.4 PEGylated Proteins & Polypeptides Revenue Growth Rate (2014-2024)
• 10.5 Polymer Nanoparticle Revenue Growth Rate (2014-2024)
• 10.6 Protein–drug Conjugates Revenue Growth Rate (2014-2024)
• 10.7 Others Revenue Growth Rate (2014-2024)

11 Global Drug Delivery in Cancer Market Segment by Application

• 11.1 Global Drug Delivery in Cancer Revenue Market Share by Application (2014-2019)
• 11.2 Drug Delivery in Cancer Market Forecast by Application (2019-2024)
• 11.3 Hospitals & Clinic Revenue Growth (2014-2019)
• 11.4 Cancer Treatment Centers Revenue Growth (2014-2019)
• 11.5 Others Revenue Growth (2014-2019)

12 Global Drug Delivery in Cancer Market Size Forecast (2019-2024)

• 12.1 Global Drug Delivery in Cancer Market Size Forecast (2019-2024)
• 12.2 Global Drug Delivery in Cancer Market Forecast by Regions (2019-2024)
• 12.3 North America Drug Delivery in Cancer Revenue Market Forecast (2019-2024)
• 12.4 Europe Drug Delivery in Cancer Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific Drug Delivery in Cancer Revenue Market Forecast (2019-2024)
• 12.6 South America Drug Delivery in Cancer Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa Drug Delivery in Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology